Trials / Completed
CompletedNCT01764243
Safety and Efficacy of MT-4666
A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy as assessed by the Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of MT-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-4666 | low dose, high dose |
| DRUG | Placebo |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2015-06-01
- Completion
- 2015-07-01
- First posted
- 2013-01-09
- Last updated
- 2015-09-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01764243. Inclusion in this directory is not an endorsement.